Retinal Vein Occlusion – Executive Insights – Executive Insights (US)
Retinal vein occlusion (RVO) is a major cause of blindness in the major pharmaceutical markets. Patients are segmented by the anatomic location of the occlusion; thus, they are classified as having branch, central, or hemi-retinal vein occlusion (BRVO, CRVO, HRVO, respectively). Because RVOs compromise venous return from the retinal circulation, they may trigger retinal ischemia, macular edema, and/or neovascularization. The standards of care for macular edema following RVO include the anti-VEGFs Eylea (Regeneron / Bayer), Lucentis (Roche / Genentech), and off-label Avastin (Roche / Genentech) and the corticosteroid implant Ozurdex (AbbVie). Notably, Roche / Chugai expect to submit an expanded application for Vabysmo for BRVO and CRVO in the United States and Europe in 2023. Although the number of therapies in development for RVO is small, commercial opportunity remains for therapies with a longer dosing duration, greater efficacy, and/or a convenient route of administration.
QUESTIONS ANSWERED
- What diagnostic tests are used to characterize RVO patients, and how are different patient subtypes treated?
- What are the physician-perceived advantages and disadvantages of current therapies?
- What are the key areas of unmet need and opportunity in the RVO market?
- What are the key strengths, weaknesses, drivers, and constraints of the RVO market?
- What influence does each major player hold over the RVO market?
- What are the competitive landscape and the expected future influence of key emerging therapies, including Roche / Chugai’s Vabysmo, in the treatment of RVO?
GEOGRAPHY
United States
PRIMARY RESEARCH
3 KOL interviews in July 2023
KEY COMPANIES COVERED
Regeneron, Roche/Genentech, AbbVie (legacy Allergan), Biogen, Coherus, Annexin, 3T Ophthalmics
KEY DRUGS COVERED ANXV, Avastin, Byooviz, Cimerli, Eylea, Eylea HD, Lucentis, Ozurdex, ONS-5010 (Lytenava), RG-7921
PRODUCT DESCRIPTION
Executive Insights provides indication-specific market intelligence with world-class epidemiology, keen insight into current treatment paradigms, biotherapeutic pipelines, key clinical unmet needs, and competitive landscapes, supported by primary and secondary research. This solution provides succinct insights to any biopharma function or business professional looking to quickly grasp a new indication of interest.
Table of contents
- Retinal Vein Occlusion - Executive Insights - Executive Insights (US)
- Executive Insights - 2023 - Retinal Vein Occlusion
John Crowley, Ph.D., is the principal director of the Infectious, Niche, & Rare Diseases team at DRG, part of Clarivate. Prior to his current role, he was a director on the team overseeing syndicated and custom work on niche and rare disease markets, as well as atopic dermatitis content in DRG’s Dermatology portfolio. He also served as a DRG analyst in the neurology space, focused mainly on the multiple sclerosis market. Dr. Crowley holds a Ph.D. from the University of Massachusetts Medical School and a bachelor’s degree from Worcester Polytechnic Institute.